Convergence Partners’ Post

Reposting from a couple of days ago so visible to anyone. It's good to see the Japanese government reducing barriers to entry for life science innovations. Getting through regulatory hurdles is a first step. Next is how to actually get and grow sales :) #JapanBusiness #LifeSciences https://lnkd.in/eyXdpGxJ

Health equity isn't just a future we imagine, it's a future we need to create. Diverse and inclusive clinical trials are crucial for ensuring everyone, irrespective of their background, benefits from medical advancements. This dialogue at #AGHE is a powerful step towards revolutionizing clinical trials and paving the way for a future where everyone has a chance at a healthier life. #WEF24 #worldeconomicforum #diversityandinclusion

Imagine a future where everyone benefits from medical advancements, regardless of their background. This is the promise of diverse and inclusive clinical trials, where research reflects the populations it aims to serve. On January 17th at the #AGHE, PFP.NGO’s #WorldEconomicForum Side Event, we are bringing together leading experts to make this vision a reality.     Join us for "Achieving Diversity and Inclusion in Clinical Trials", a dynamic discussion exploring the current state of diversity in clinical trials, barriers preventing #underrepresented groups from participating, innovative approaches to increase inclusivity in research, and strategies for building trust with diverse communities.    Hear from our esteemed panelists, trailblazers in shaping a more equitable future for medicine:  Chris Benko, Chief Executive Officer Koneksa Health   Nadir AMMOUR, Global Lead of Clinical Innovation & External Partnerships at Sanofi  Nhlanhla Msomi, PhD , President & Chairman at AfricaBio and BoD at Next Biosciences  Martin Unverdorben, Vice President, Global Head Specialty Medical Affairs at Daiichi Sankyo  Andreas Halner, President and Co-Founder at Oxford Cancer Analytics Joseph K., Chief Strategy Officer at ProofPilot   Mimi Choon-Quinones, LLM., MBA., PhD MRD in Blood Cancers Chairperson &Founder of Partners For Patients NGO   Meet the Moderators:  Nyasha Zimucha, Chief Diversity, Equity, & Inclusion Officer & Founder at Bubbles and Bridges and Former Miss Africa   Kevin Schorr, Life Sciences Commercialization Lead at Acquis Consulting Group + Programming Lead Partners For Patients NGO   Together, we can revolutionize #clinicaltrials, ensuring equitable access to life-saving research for all, medical advancements that reflect the diversity of our population, and a future where healthcare truly serves everyone.    Don't miss this vital conversation! Register today:  https://lnkd.in/daSMSSf3 #WEF24 #Davos #diversityinclunsion #futureofmedicine #accesstocare

https://lnkd.in/dmZtzp-T I am elated to share a copy of the conversation I had with Executive Forecast on the work MeDDIC has done and will continue to do in the MedTech Ecosystem and how this aligns with the recently published national MedTech master plan.  I hope I will follow this up with conversations of other entrepreneurs and technologies supported by the programme that are successfully procured in 2 provincial hospitals (in South Africa) and another company now selling in the USA. Hopefully for my friends and family who always ask me what I do, this is a nice summary of what I do and why. To my colleagues, our funders and stakeholders, we would not have made half the strides if it weren't for your support, openness and frank conversations on what needs to be done. The Medtech Masterplan is published, it is up to us in our individual and collective actions to do our best to implement it, review the progress as we go along and make adjustments where necessary. For now, cheers to everyone trying to increase localization of medical devices and diagnostics (well and everything else) and provide equitable access. 

𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/d3zjTYCp The Virtual Clinical Trials Market was valued at USD 7.73 billion in 2021 and is projected to grow steadily, reaching USD 15.3 billion by 2032 with a CAGR of 6.4%. Also known as decentralized trials, virtual clinical trials represent a relatively new approach in health research utilizing digital technologies to collect data remotely from participants in their everyday environments. Key benefits include cost efficiencies, increased patient engagement, enhanced data capture, and streamlined research processes. The market's growth is driven by expanding adoption of virtual trial methods, coupled with rising global incidences of various illnesses and chronic conditions. Furthermore, advancements in technology within clinical research are expected to further boost market expansion. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐒𝐭𝐮𝐝𝐲 𝐓𝐲𝐩𝐞: Interventional, Observational, Expanded Access. ▶𝐏𝐡𝐚𝐬𝐞: Phase I, Phase II, Phase III, Phase IV. ▶𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧: CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others. ▶𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧: North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA      𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝: Accenture, Oracle, J&J Innovative Medicine Italia, IQVIA, Labcorp Drug Developement., ICON plc, Dassault Systèmes, Parexel, Clario, Medpace., Medidata Solutions, Signant Health, Medable, Inc, Clinical ink, Croprime Ltd   #VirtualClinicalTrials #DecentralizedTrials #RemoteClinicalResearch #DigitalHealth #PatientCentricTrials #TelemedicineResearch #VirtualTrials #ClinicalTrialInnovation #RemoteMonitoring #VirtualResearch #DigitalTrials #eClinicalTrials #ClinicalResearchTech #TelehealthStudies #VirtualHealthcare #RemotePatientTrials #ClinicalTrialTechnology #DecentralizedResearch #VirtualPatientJourney #DigitalClinicalTrials

The #BioRegion has kicked off the new year with #research and #entrepreneurship initiatives to continue consolidating the sector: 🩸 The Hospital de la Santa Creu i Sant Pau took part in an international study that has shown that blood tests can be effective in diagnosing #Alzheimer. 🤰 The second birth in Spain from a transplanted uterus has taken place at the Hospital Clínic de Barcelona. 🧠 The Hospital Universitari de Bellvitge has become the first Catalan public center to start using transcranial magnetic stimulation to treat resistant #depression.   But also, January has been a month of expansion for many companies in the #BioRegion: 🔺 #TopHealthTech (Top Doctors), which specializes in developing #AI for #healthcare, won a tender in the UK to create a workplace #health portal. 🔺 Cuideo ® has acquired the company Dpen-D (Grupo Cuideo) and now serves 500,000 policyholders. 🔺 nen has launched its first product, #nendo, a program designed specifically for paediatric #cancer patients. 🔺 Oniria Therapeutics has been awarded €964,000 through the Spanish Ministry of Science and Innovation.   More news 👇 https://tuit.cat/zykxT

👀 Did you miss the roundtable "Catalonia Advanced Therapies Ecosystem: Building Europe’s Future in ATMPs" at #RESIEurope2024? You can watch the recording of the debate here 👇 ▶️ https://lnkd.in/dYUZ8Cq5 The panel discussion highlighted the key role Catalonia’s advanced therapies will play in innovation and clinical breakthroughs in Europe. As Robert Fabregat Fuentes (#Biocat's CEO) emphasized: Catalonia ranks 5th in Europe and 8th worldwide in participation in clinical trials of #ATMPs. Moreover, the #BioRegion stands out in the number of publications on advanced therapies. 🗣 Luis Pareras MD, PhD (Invivo Partners) pointed to the quality of Catalan research: "In the field of advanced therapies and synthetic #biology, we have some of the best scientists in Europe and the world." For the roundtable participants, the main challenges posed by advanced therapies include attracting qualified #talent and ensuring patients' access to therapies. 🗣 Fina Lladós Canela (Amgen España) highlighted the need to scale up therapy production and ensure patient access: "It makes no sense to invest and attract innovation if it does not reach patients." Similarly, Esteve Trias i Adroher (Leitat Technological Center) expressed that while Catalonia is strong at both the beginning and end of the chain, it is fundamental to 💬 "build this bridge between research and transfer." 🗣 For Silvia Martín Lluesma (Vall d'Hebron Institute of Oncology (VHIO)), what is crucial is that researchers, clinicians, and regulatory professionals work hand in hand in the development of advanced therapies. To address these and other challenges in advanced therapies, Antoni Matilla Dueñas (BIOINTAXIS) brought up the recent creation of the Advanced Therapies Network of Catalonia, coordinated by #Biocat. 👉 This network aims to promote #research, manufacturing, and development of #AdvancedTherapies to make them accessible to the public efficiently and sustainably. #RESIEUROPE #RESIBARCELONA #RESI #ATMPs #AdvancedTherapies Life Science Nation

After a year of intense work, it appears that we have discovered a promising biomarker for diagnosing ALS (Amyotrophic Lateral Sclerosis). Our team has developed a fully non-invasive technique that is based on tear analyses, takes just 5 to 15 minutes to complete, and is reasonably accurate. In our preclinical evaluation involving a cohort of about 30 patients and controls, the method demonstrated a remarkable 100% specificity and 82% sensitivity. These promising results bring us one step closer to a more efficient and non-invasive diagnostic process for ALS. We are now planning clinical studies to further validate our findings. The study will be conducted in both Iran and Canada, broadening the scope of our research and bringing us closer to our goal of making this method accessible to all. A special thanks to Faezeh Rasti and Abbas Ali Khodadadi for their invaluable contributions and relentless efforts. https://lnkd.in/dgEquwYx #ALS #Research #Innovation #Healthcare #Diagnostics

🌟 "Diving into the world of Life Sciences, Astellas Pharma US highlights a growing trend: the complexity of industry-academic partnerships is on the rise, mirroring the intricate landscape of Life Science research itself. 🧬🤝 Navigating this complexity, especially when it comes to ensuring data is shared accurately, completely, and securely, often becomes a hurdle too high for effective collaboration. 🚧 🔍 Curious about how to clear this hurdle with ease? The Genestack platform ODM is your answer to seamless collaboration. 💡✨ 👇 **Want in on the secret to effortless collaboration? Drop a comment below. #LifeSciences #Biotech #AcademicPartnerships #DataSharing #Innovation #Collaboration #PharmaIndustry #ResearchAndDevelopment #DigitalTransformation #Genestack

Bridging Biomedical Innovation Across Borders: Brazil's Leadership in Affordable Healthcare In an enlightening piece by ed silverman for STAT, a transformative approach to biomedical development is unveiled, spotlighting the strides being made in South-South collaborations. These partnerships are not just reshaping the healthcare landscape; they are a testament to a world where advanced medical treatments can be accessible to all. Brazil, under the guidance of Caring Cross, has embarked on a commendable venture with the Brazilian Ministry of Health. This initiative is set to localize the production of CAR-T cell therapies, traditionally exorbitant, and now expected to cost merely a fraction of their usual price—about $40,000 per patient compared to the hundreds of thousands in more affluent nations. This effort aligns seamlessly with Brazil's broader vision of harnessing biomedical innovation to tackle pressing public health challenges. By integrating unique expertise and resources, the plan is to produce and provide treatments for diseases like lymphoma and leukemia at significantly reduced costs, thus democratizing access to cutting-edge therapies. This narrative isn't singular. Check out an article I posted recently titled “The Transformative Power of Language in Business and Science", detailing a collaboration between India and Mexico aimed at developing low-cost biomedical solutions. Such 'weak signals' are potent indicators of shifting trends towards more inclusive and sustainable healthcare models, especially in the Global South. At Zentynel, we are committed to spotlighting these pivotal moments in healthcare that promise a more hopeful and health-secure future for all. By fostering an ecosystem that supports innovation and affordability, countries like Brazil are not only leading but also inspiring a global movement. To our Brazilian readers, what are your thoughts on these innovative initiatives in your country? How do you see these affecting your community and healthcare system? Let's continue to push the boundaries of what's possible in healthcare, driven by vision, leadership, and the collective will to ensure health for all. #ZentynelVC #BiomedicalInnovation #AffordableHealthcare #GlobalHealth #HealthTech #ScienceAndBusiness